FAFatma Aydın

Fatma Aydın

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fatma Aydın has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiometabolic Inflammation in Vitiligo: Association with Metabolic Syndrome and Inflammatory Biomarkers

    by Belkis Meryem Feldmann, Esra Pancar Yüksel, Gökhan Şahin, Bahattin Avcı, Fatma Aydın

    Background: Vitiligo, previously considered a localized skin disease, is now regarded as a systemic condition due to its association with autoimmune and metabolic abnormalities. The relationship between metabolic syndrome (MetS) and vitiligo is not clearly established. Chronic inflammation and oxidative stress may also contribute to inflammation-related cardiometabolic processes, even in the absence of MetS. Objectives: To investigate MetS components and inflammatory biomarkers (TNF-α, IL-6, GDF-15, and CCL-7) in patients with vitiligo without comorbidities and to compare the findings with healthy individuals. Methods: In this case–control study, 43 patients with vitiligo and 43 frequency-matched controls (18–65 years) were included. Participants with systemic diseases, smoking or alcohol use, or medications affecting metabolic parameters were excluded. Disease severity and activity were assessed using VASI, BSA, and VIDA scores. Anthropometric data, blood pressure, and laboratory parameters were recorded. Serum biomarker levels were measured by ELISA. Results: The two groups were similar in terms of age and sex. Systolic blood pressure was higher in the vitiligo group (P=0.011), whereas other metabolic parameters and MetS prevalence were comparable. Longer disease duration was associated with the presence of MetS (P=0.008). TNF-α, IL-6, GDF-15, and CCL-7 levels were significantly higher in patients than controls. Among these, GDF-15 and CCL-7 were associated with disease activity, while TNF-α and IL-6 were not. Multivariable regression analysis demonstrated that GDF-15 remained independently associated with vitiligo after adjusting for age, sex, and BMI, whereas the association with CCL-7 was no longer statistically significant. Conclusion: MetS prevalence was not increased in vitiligo; however, elevated inflammatory biomarkers may reflect inflammation-related cardiometabolic processes. After adjusting for age, sex, and BMI, GDF-15 remained independently associated with vitiligo, whereas the association with CCL-7 was no longer statistically significant.

  • Open Access

    Cardiometabolic Inflammation in Vitiligo: Association with Metabolic Syndrome and Inflammatory Biomarkers

    by Belkis Meryem Feldmann, Esra Pancar Yüksel, Gökhan Şahin, Bahattin Avcı, Fatma Aydın

    Background: Vitiligo, previously considered a localized skin disease, is now regarded as a systemic condition due to its association with autoimmune and metabolic abnormalities. The relationship between metabolic syndrome (MetS) and vitiligo is not clearly established. Chronic inflammation and oxidative stress may also contribute to inflammation-related cardiometabolic processes, even in the absence of MetS. Objectives: To investigate MetS components and inflammatory biomarkers (TNF-α, IL-6, GDF-15, and CCL-7) in patients with vitiligo without comorbidities and to compare the findings with healthy individuals. Methods: In this case–control study, 43 patients with vitiligo and 43 frequency-matched controls (18–65 years) were included. Participants with systemic diseases, smoking or alcohol use, or medications affecting metabolic parameters were excluded. Disease severity and activity were assessed using VASI, BSA, and VIDA scores. Anthropometric data, blood pressure, and laboratory parameters were recorded. Serum biomarker levels were measured by ELISA. Results: The two groups were similar in terms of age and sex. Systolic blood pressure was higher in the vitiligo group (P=0.011), whereas other metabolic parameters and MetS prevalence were comparable. Longer disease duration was associated with the presence of MetS (P=0.008). TNF-α, IL-6, GDF-15, and CCL-7 levels were significantly higher in patients than controls. Among these, GDF-15 and CCL-7 were associated with disease activity, while TNF-α and IL-6 were not. Multivariable regression analysis demonstrated that GDF-15 remained independently associated with vitiligo after adjusting for age, sex, and BMI, whereas the association with CCL-7 was no longer statistically significant. Conclusion: MetS prevalence was not increased in vitiligo; however, elevated inflammatory biomarkers may reflect inflammation-related cardiometabolic processes. After adjusting for age, sex, and BMI, GDF-15 remained independently associated with vitiligo, whereas the association with CCL-7 was no longer statistically significant.

  • Open Access

    Evaluation of Anthropometric Measurements, Arterial Stiffness and ECG Parameters in Alopecia Areata Patients

    by Esra Pancar Yuksel, Gokhan Sahin, Mustafa Cagri Sahin, Sedanur Ozdemir Karadavut, Serkan Yuksel, Fatma Aydin

    Background and Objectives: Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss and has been associated with systemic immune-inflammatory activity and potential cardiometabolic risk. This study aimed to evaluate cardiovascular risk markers—including ECG parameters, arterial stiffness indices, anthropometric measurements, and body composition—in patients with AA according to disease severity and duration, and to compare these findings with healthy controls. Materials and Methods: This case–control study included 50 AA patients (32 men, 18 women; mean age: 28.98 ± 9.81 years) and 50 healthy controls (30 men, 20 women; mean age: 28.00 ± 7.86 years). All participants underwent anthropometric and electrocardiographic evaluations. Body composition was assessed, and arterial stiffness was measured. Subgroup analyses were performed according to SALT score (mild vs. moderate-to-severe) and disease duration (≥10 years vs. Results: Heart rate was lower in AA patients compared with controls (mean difference −5.14 bpm; 95% CI −10.267 to −0.013). No significant differences were found between the groups regarding anthropometric variables, body composition, or arterial stiffness indices. Among AA patients, those with moderate-to-severe disease had significantly lower body fat mass (mean difference 4.95 kg; 95% CI 0.26 to 9.644) and lower visceral fat rating (mean difference 2.428 units; 95% CI 0.800 to 4.056) compared with mild AA. Conclusions: AA patients demonstrated lower heart rate and disease-severity-related alterations in body composition, although the clinical significance of these findings remains uncertain. Larger longitudinal studies are needed to clarify whether these subclinical differences translate into meaningful cardiovascular risk over time.

  • Open Access

    Systemic Treatments in Pediatric Psoriasis: A Retrospective Single-Center Study

    by Gokhan Sahin, Fatma Aydin, Esra Pancar Yuksel

    Background: Systemic therapies commonly used in adult psoriasis are mostly used only off-label in children and little is known about the efficacy and tolerability of these drugs in this population. In this study, we aimed to evaluate the efficacy and safety of systemic treatments in pediatric patients with psoriasis. Methods: Data were obtained retrospectively from the Department of Dermatology, Ondokuz Mayis University, School of Medicine between 2010–2019. Our study consisted of 742 pediatric patients (age ≤18 years) with psoriasis. Demographic data, adverse events of systemic treatments and healing periods were considered. Results: A total of 195 patients received systemic treatment. The mean age of onset of disease and the initiation of systemic therapy were 9.68±4.62 and 11.33±4.38 years, respectively. Patients received methotrexate (n=52, 26.67%), cyclosporine (n=18, 9.24%), acitretin (n=106, 54.35%) and others (biologics and/or one of conventional treatments) (n=19, 9.74%) as systemic therapy. Adverse events occurred in 12 patients (incidence of 6.15%, and its related 95% confidence interval of 2.75%, 9.56%) and nine of them had to discontinue the medication due to those adverse events. Healing periods calculated in the remaining 186 patients were 13.25±5.87, 10.85±5.67, 11.05±7.00, and 9.41±4.16 (mean±SD) weeks for acitretin, methotrexate, cyclosporine, and others, respectively. No statistically significant differences were noted between the treatments regarding the healing periods. Conclusion: All treatments were effective and none of them was superior in terms of the healing period. Systemic treatments used in adults can also be used in pediatric patients with psoriasis with similar efficacy and safety rates as long as routine monitoring is provided.


  • Androgenetik Alopesi

    by Gökhan Şahi̇n, Hilal Özdemi̇r, Fatma Aydin

    Androgenetik alopesi genetik yatkınlığı olan kişilerde farklı patolojik mekanizmalarla ortaya çıkabilen, erkek ve kadınlarda kliniği değişiklik gösterebilen bir saç dökülme şeklidir. Androgenetik alopesi her ne kadar sık görülüyor ve tanısı genellikle kolay koyuluyor olsa da hasta yönetimi için standart bir tedavi rehberi yoktur. Androgenetik alopesi yönetiminde amaç foliküler minyatürizasyonu durdurmak ve saç dansitesini arttırmaktır. Androgenetik alopesi yönetiminde kullanılan tedaviler potasyum iyon kanalı düzenleyicileri (topikal minoksidil ve oral minoksidil), 5α redüktaz inhibitörleri (oral finasterid, topikal finasterid ve oral dutasterid), androjen reseptör antagonistleri (spironolak-ton, siproteron asetat, flutamid, korteksolon 17 alfa propionat ve topikal fluridil), diğer medikal tedaviler (topikal prostoglandin analogları, topikal ketokonazol, topikal melatonin, Wnt/β katenin sinyal yolağı aktivatörleri ve JAK-STAT yolağı inhibitörleri), fiziksel tedaviler (düşük dereceli lazer ışık tedavisi, lazer tedavileri, mikroiğneleme, mezoterapi, PRP ve kök hücre tedavileri), tamamlayıcı tedaviler (saç transplantasyonu, besin takviyeleri ve kamuflaj yöntemleri) ve kombinasyon tedavileridir. Bu derlemede erkek ve kadında androgenetik alopesi yönetiminde güncel tedavi yöntemleri hakkında bilgi verilmesi amaçlanmıştır.

  • Sweets Syndrome and Different Clinical Faces

    by Fatma Aydın, Nalan Saraç